Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566

R. M.J. Deacon, M. J. Hurley, C. M. Rebolledo, M. Snape, F. J. Altimiras, L. Farías, M. Pino, R. Biekofsky, L. Glass, P. Cogram

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Retraction: "Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566" by R. M. J. Deacon, M. J. Hurley, C. M. Rebolledo, M. Snape, F. J. Altimiras, L. Farías, M. Pino, R. Biekofsky, L. Glass and P. Cogram. The above article, from Genes, Brain and Behavior, published online on 12th May 2017 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor in Chief, Andrew Holmes and John Wiley & Sons Ltd. The retraction has been agreed as all authors cannot agree on a revised author order, and at least one author continues to dispute the original order. In this case, the original article is being retracted on the grounds that the journal does not have permission to publish. Reference: Deacon, R. M. J., Hurley, M. J., Rebolledo, C. M., Snape, M., Altimiras, F. J., Farías, L., Pino, M., Biekofsky, R., Glass, L. and Cogram, P. (2017), Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566. Genes, Brain and Behavior. doi:10.1111/gbb.12373.

Original languageEnglish
Pages (from-to)739
Number of pages1
JournalGenes, brain, and behavior
Volume16
Issue number7
DOIs
StatePublished - 1 Sep 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566'. Together they form a unique fingerprint.

Cite this